Drotrecogin alfa (original) (raw)
Drotrecogin alfa (activated) (Xigris, marketed by Eli Lilly and Company) is a recombinant form of human activated protein C that has anti-thrombotic, anti-inflammatory, and profibrinolytic properties. Drotrecogin alpha (activated) belongs to the class of serine proteases. Drotrecogin alfa has not been found to improve outcomes in people with severe sepsis. The manufacturer's aggressive strategies in marketing its use in severe sepsis have been criticized. On October 25, 2011, Eli Lilly & Co. withdrew Xigris from the market after a major study showed no efficacy for the treatment of sepsis.
| Property | Value |
|---|---|
| dbo:abstract | Drotrecogin (Handelsname: Xigris®, Hersteller: Lilly) ist eine rekombinante Form des natürlicherweise im Blutplasma vorkommenden aktivierten Protein C, rhAPC (rekombinantes aktiviertes Protein C), von dem es sich nur durch einzelne Oligosaccharide im Kohlenhydratteil des Moleküls unterscheidet. Drotrecogin gehört zu den Serinproteasen. Es war in der Intensivmedizin bei Erwachsenen im Fall einer schweren Sepsis mit multiplen Organversagen zusätzlich zur Standardtherapie gedacht und unter bestimmten Bedingungen empfohlen. Das Medikament wurde 2011 vom Markt genommen, nachdem die anfängliche positive Nutzen-Risiko-Bewertung nicht aufrechterhalten werden konnte. Drotrecogin wird gentechnisch aus einer etablierten humanen Zelllinie hergestellt. Es unterscheidet sich von dem natürlicherweise im Plasma vorkommenden aktivierten Protein C durch einzelne an dieses Protein gebundene Oligosaccharide. (de) Drotrecogin alfa (activated) (Xigris, marketed by Eli Lilly and Company) is a recombinant form of human activated protein C that has anti-thrombotic, anti-inflammatory, and profibrinolytic properties. Drotrecogin alpha (activated) belongs to the class of serine proteases. Drotrecogin alfa has not been found to improve outcomes in people with severe sepsis. The manufacturer's aggressive strategies in marketing its use in severe sepsis have been criticized. On October 25, 2011, Eli Lilly & Co. withdrew Xigris from the market after a major study showed no efficacy for the treatment of sepsis. (en) Drotrekogina alfa (ang. drotrecogin alfa) – lek wykazujący działanie przeciwzakrzepowe i przeciwzapalne. Lek ma postać aktywowanego białka C wytwarzanego metodami inżynierii genetycznej w hodowli komórek ludzkich. Białko to bierze udział w procesach krzepnięcia krwi i reakcji zapalnej. (pl) Drotrecogin alfa är ett läkemedel (Xigris) för kliniskt bruk av svår sepsis. Läkemedlet består av det kroppsegna protein C som reglerar koagulationen. Denna läkemedels- eller farmakologi-relaterade artikel saknar väsentlig information. Du kan hjälpa till genom att lägga till den. (sv) A drotregogina ou drotregogina alfa ativada é um fármaco utilizado como antifibrinolítico inibindo o inativador do plasminogénio. Tem também uma ação anti-inflamatória. (pt) |
| dbo:alternativeName | Xigris (en) |
| dbo:bioavailability | 100.000000 (xsd:float) |
| dbo:casNumber | 98530-76-8 |
| dbo:drugbank | DB00055 |
| dbo:fdaUniiCode | JGH8MYC891 |
| dbo:wikiPageExternalLink | https://www.fda.gov/medwatch/SAFETY/2005/xigris_USPI_17Dec04.pdf |
| dbo:wikiPageID | 1707323 (xsd:integer) |
| dbo:wikiPageLength | 15203 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1124066616 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Protein_C dbr:Brand_name dbr:Anti-inflammatory dbr:Clopidogrel dbr:Eli_Lilly_and_Company dbr:Leukocyte dbr:Plasminogen_activator_inhibitor-1 dbc:Intensive_care_medicine dbr:Warfarin dbr:Tumor_necrosis_factors dbr:APACHE_II dbc:Antithrombotic_enzymes dbr:Food_and_Drug_Administration dbr:Recombinant_DNA dbc:Withdrawn_drugs dbr:Aspirin dbc:Eli_Lilly_and_Company_brands dbr:New_England_Journal_of_Medicine dbr:Sepsis dbr:Serine_protease dbr:Intravenous dbr:Thrombosis dbr:Selectin dbr:Cochrane_review |
| dbp:atcPrefix | B01 (en) |
| dbp:atcSuffix | AD10 (en) |
| dbp:bioavailability | 100.0 (dbd:perCent) |
| dbp:c | 1786 (xsd:integer) |
| dbp:casNumber | 98530 (xsd:integer) |
| dbp:chemspiderid | none (en) |
| dbp:drugbank | DB00055 (en) |
| dbp:eliminationHalfLife | 7200.0 (dbd:second) |
| dbp:h | 2779 (xsd:integer) |
| dbp:iupacName | Activated human protein C (en) |
| dbp:iupharLigand | 6788 (xsd:integer) |
| dbp:legalStatus | Rx-only (en) |
| dbp:metabolism | endogenous plasma protease inhibitors (en) |
| dbp:n | 509 (xsd:integer) |
| dbp:o | 519 (xsd:integer) |
| dbp:routesOfAdministration | dbr:Intravenous |
| dbp:s | 29 (xsd:integer) |
| dbp:tradename | Xigris (en) |
| dbp:unii | JGH8MYC891 (en) |
| dbp:verifiedfields | changed (en) |
| dbp:verifiedrevid | 457450996 (xsd:integer) |
| dbp:wikiPageUsesTemplate | dbt:Antithrombotics dbt:Citation_needed dbt:Drugbox dbt:Reflist dbt:When dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Drugs.com dbt:Intensive_care_medicine |
| dct:subject | dbc:Intensive_care_medicine dbc:Antithrombotic_enzymes dbc:Withdrawn_drugs dbc:Eli_Lilly_and_Company_brands |
| gold:hypernym | dbr:Form |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatAnticoagulants yago:WikicatWithdrawnDrugs yago:Agent114778436 yago:Anticoagulant102718259 yago:CausalAgent100007347 yago:Drug103247620 yago:Matter100020827 yago:Medicine103740161 yago:PhysicalEntity100001930 dbo:Drug yago:Substance100020090 umbel-rc:DrugProduct |
| rdfs:comment | Drotrecogin alfa (activated) (Xigris, marketed by Eli Lilly and Company) is a recombinant form of human activated protein C that has anti-thrombotic, anti-inflammatory, and profibrinolytic properties. Drotrecogin alpha (activated) belongs to the class of serine proteases. Drotrecogin alfa has not been found to improve outcomes in people with severe sepsis. The manufacturer's aggressive strategies in marketing its use in severe sepsis have been criticized. On October 25, 2011, Eli Lilly & Co. withdrew Xigris from the market after a major study showed no efficacy for the treatment of sepsis. (en) Drotrekogina alfa (ang. drotrecogin alfa) – lek wykazujący działanie przeciwzakrzepowe i przeciwzapalne. Lek ma postać aktywowanego białka C wytwarzanego metodami inżynierii genetycznej w hodowli komórek ludzkich. Białko to bierze udział w procesach krzepnięcia krwi i reakcji zapalnej. (pl) Drotrecogin alfa är ett läkemedel (Xigris) för kliniskt bruk av svår sepsis. Läkemedlet består av det kroppsegna protein C som reglerar koagulationen. Denna läkemedels- eller farmakologi-relaterade artikel saknar väsentlig information. Du kan hjälpa till genom att lägga till den. (sv) A drotregogina ou drotregogina alfa ativada é um fármaco utilizado como antifibrinolítico inibindo o inativador do plasminogénio. Tem também uma ação anti-inflamatória. (pt) Drotrecogin (Handelsname: Xigris®, Hersteller: Lilly) ist eine rekombinante Form des natürlicherweise im Blutplasma vorkommenden aktivierten Protein C, rhAPC (rekombinantes aktiviertes Protein C), von dem es sich nur durch einzelne Oligosaccharide im Kohlenhydratteil des Moleküls unterscheidet. Drotrecogin gehört zu den Serinproteasen. Es war in der Intensivmedizin bei Erwachsenen im Fall einer schweren Sepsis mit multiplen Organversagen zusätzlich zur Standardtherapie gedacht und unter bestimmten Bedingungen empfohlen. Das Medikament wurde 2011 vom Markt genommen, nachdem die anfängliche positive Nutzen-Risiko-Bewertung nicht aufrechterhalten werden konnte. (de) |
| rdfs:label | Drotrecogin (de) Drotrecogin alfa (en) Drotrekogina alfa (pl) Drotrecogina alfa (pt) Drotrecogin alfa (sv) |
| owl:sameAs | freebase:Drotrecogin alfa http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00055 yago-res:Drotrecogin alfa wikidata:Drotrecogin alfa dbpedia-de:Drotrecogin alfa dbpedia-pl:Drotrecogin alfa dbpedia-pt:Drotrecogin alfa dbpedia-sh:Drotrecogin alfa dbpedia-sr:Drotrecogin alfa dbpedia-sv:Drotrecogin alfa https://global.dbpedia.org/id/3ppZr |
| prov:wasDerivedFrom | wikipedia-en:Drotrecogin_alfa?oldid=1124066616&ns=0 |
| foaf:isPrimaryTopicOf | wikipedia-en:Drotrecogin_alfa |
| is dbo:wikiPageRedirects of | dbr:ATC_code_B01AD10 dbr:ATCvet_code_QB01AD10 dbr:Xigris dbr:Drotrecogin_alfa_(activated) dbr:Drotrecogin_alpha dbr:Activated_drotrecogin_alfa dbr:Recombinant_activated_protein_C |
| is dbo:wikiPageWikiLink of | dbr:Protein_C dbr:Proteases_(medical_and_related_uses) dbr:ATC_code_B01AD10 dbr:ATCvet_code_QB01AD10 dbr:ATC_code_B01 dbr:Disseminated_intravascular_coagulation dbr:Xigris dbr:List_of_withdrawn_drugs dbr:List_of_drugs:_Dr–Dy dbr:Drotrecogin_alfa_(activated) dbr:Drotrecogin_alpha dbr:Activated_drotrecogin_alfa dbr:Recombinant_activated_protein_C |
| is rdfs:seeAlso of | dbr:Protein_C |
| is foaf:primaryTopic of | wikipedia-en:Drotrecogin_alfa |